Here is a question for the pharmacists amongst us.
In Perth, Moclobemide, a reversible monoamine oxidase inhibitor, is becoming
popular for the treatment of postnatal depression. The drug company mentions
that about 1/30 of mother's dose enters breastmilk, and they give the usual
comment about benefit outweighing risk. Does anyone know of any study that
has been done into this, as I am dubious about using SSRIs on lactating women
(eg Prozac, Zoloft etc), but mothers often find the side-effects of the older
tricyclic drugs offputting. Comments anyone??

Fiona Coombes (sometimes confused doc and LC)
Perth Western Australia